Article

RLE with pseudoaccommodative IOL shows promise

A new accommodating lens seems to be a safe option for properly selected patients, in whom excellent refractive results can be achieved.

Key Points

Dr. Shah presented data from a consecutive case series of 78 eyes that underwent clear lens extraction. The mean patient age was 51 years (range, 43 to 60 years). Thirty eyes were myopic (mean refraction, –12.0 D), and the remainder were hyperopic (mean refraction, +6.5 D), according to Dr. Shah. He is a consultant ophthalmic surgeon at the Birmingham and Midland Eye Centre, Birmingham, and the Midland Eye Institute, Solihull, U.K.

The IOL is a square-edged acrylic lens that can be injected through a 2.8-mm incision. Dr. Shah described the insertion procedure as very easy to perform, with no preoperative or postoperative care requirements.

"The best-corrected visual acuity (BCVA) was about 0 LogMAR. No patients lost a substantial amount of BCVA. One patient lost one line of vision (from 20/15 to 20/20). A large percentage of patients gained BCVA."

Quality of vision

This IOL is a pseudoaccommodative lens. When accommodation was measured with a push-pull technique, Dr. Shah said, "the mean subjective accommodative amplitude was about 2.4 ± 1.0 D 6 months after implantation. The lowest accommodative amplitude was 1.5 D, and the highest was 4.4 D. In another group of patients who underwent cataract extraction, some patients had up to 6.5 D of subjective accommodation."

With this type of IOL, Dr. Shah said, it is difficult to determine exactly how it works. "Objective tests of these lenses with automated refractors show lower values on the same patient than the subjective tests, yet the patients are very happy. So something that we are not measuring well must be happening.

"We achieved extremely good UCVA results with this lens that are comparable with most monofocal IOLs. The results of this study are probably better than most of the studies that have been published," Dr. Shah said. "Patient satisfaction is very high with this IOL. As with most of these types of lenses, most patients achieved very good intermediate vision, and a good percentage had good near vision. At this time, this is my standard lens for clear lens extractions."

The patients who received the IOL 2 years ago are being evaluated to determine the stability of the visual acuity over time, he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.